Jump to content

CoviVac (Russia COVID-19 vaccine)

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Kathleen.wright5 (talk | contribs) at 06:52, 15 October 2021 (removed Template:COVID-19 Vaccines - same template as Template:COVID-19 pandemic). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

This article is about the Russian vaccine. For other uses, see Covivac (disambiguation).

CoviVac
КовиВак
Vaccine description
TargetSARS-CoV-2
Vaccine typeInactivated
Clinical data
Routes of
administration		Intramuscular
ATC code
  • None
Legal status
Legal status
  • Registered in Russia on 20 February 2021

CoviVac (Russian: КовиВак) is an inactivated virus-based COVID-19 vaccine developed by the Chumakov Centre [ru],[1] which is an institute of the Russian Academy of Sciences.[2] It was approved for use in Russia in February 2021, being the third COVID-19 vaccine to get approval in Russia.[1] It obtained a permission for phase III clinical trial on 2 June 2021.[3]

Medical use

The CoviVac shot is given in two doses, 14 days apart. It is transported and stored at normal refrigerated temperatures, of 2 to 8 degrees Celsius (35.6 to 46.4 Fahrenheit).[1]

Efficacy has not yet been established in a phase III clinical trial.

Chemistry

One dose of 0.5 ml is composed only of 3 μg or more of SARS-CoV-2 strain AYDAR-1 antigen inactivated by beta-propiolactone and the following excipients:[4]

Manufacturing

As an inactivated vaccine, CoviVac uses a more traditional technology that is similar to the inactivated polio vaccine. Initially, a sample of SARS-CoV-2 strain AYDAR-1 was isolated by the Chumakov Center at the Russian Academy of Sciences and used to grow large quantities of the virus using vero cells. From then on, the viruses are soaked in beta-propiolactone, which deactivates them by binding to their genes, while leaving other viral particles intact. The resulting inactivated viruses are then mixed with an aluminium-based adjuvant.[5]

History

Authorization

  Full authorization
  Emergency authorization
  Allowed for travel
See also: List of COVID-19 vaccine authorizations § CoviVac

On 20 February 2021, President Vladimir Putin announced that the vaccine was approved.[1]


Clinical trials

A phase III trial has started and is expected to end on 30 December 2022.[6]

References

  1. ^ a b c d Ivanova P (20 February 2021). "Russia approves its third COVID-19 vaccine, CoviVac". Reuters. Retrieved 13 March 2021.
  2. ^ Abbany Z (9 March 2021). "Two more Russian vaccines: What we do and don't know". Deutsche Welle. Retrieved 13 March 2021.
  3. ^ Реестр разрешений на проведение клинических исследований лекарственных средств. (in Russian), Catalogue of permissions for conducting clinical trials of pharmaceuticals, 2 June 2021, Minzdrav
  4. ^ "КовиВак (Вакцина коронавирусная инактивированная цельновирионная концентрированная очищенная)" [CoviVac (Inactivated whole-virion concentrated, purified coronavirus vaccine)]. vidal.ru (in Russian). 24 February 2021. Retrieved 19 May 2021.
  5. ^ Kozlovskaya L, Pinyaeva A, Kovpak A, Gordeichuk I, Volok V, Ignatiev G (1 April 2021). "«КОВИВАК»: инактивированный, но активный" ["COVIVAC": inactivated but active]. indicator.ru (Interview) (in Russian). Interviewed by Vodovozov A. Retrieved 19 May 2021.
  6. ^ "Реестр разрешений на проведение клинических исследований лекарственных средств" [Register of approvals for clinical trials of medicinal products]. rosminzdrav.ru (in Russian). 2 July 2021. Retrieved 2 July 2021.
Scholia has a profile for CoviVac (Q105597762).


Stub icon

This article about the COVID-19 pandemic is a stub. You can help Wikipedia by expanding it.

Stub icon

This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it.

Stub icon

This article about COVID-19 vaccines is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=CoviVac_(Russia_COVID-19_vaccine)&oldid=1050009369"